Compstatin Analogue Composition for C3 Binding and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compstatin analogues face challenges in achieving enhanced activity and modulating pharmacokinetic properties such as increased half-life and physicochemical properties like solubility for therapeutic applications.
Innovation Solution
Development of compstatin analogues with specific modifications, including the introduction of isoleucine at position 3, charged or polar amino acids at position 9, and N- and/or C-terminal sequences, to improve binding and complement-inhibiting activity, solubility, and pharmacokinetic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If compstatin peptide is truncated to reduce molecular size, then ease of manufacture and reduced immunogenicity are improved, but biological activity is lost
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (1, 3, 4, 6, 9, 13) of the compstatin peptide. These modifications include substituting residues with structurally similar alternatives (e.g., Valine with Isoleucine or Threonine) to maintain the cyclic structure and disulfide bridge while improving pharmacokinetic properties and solubility without compromising C3 binding activity.
Solution Approach 2:
The patent applies local quality by making targeted modifications at specific positions rather than uniform changes throughout the peptide. Each position (1, 3, 4, 6, 9, 13) has specific allowable substitutions based on structural and functional considerations, allowing optimization of particular properties (solubility, stability, activity) while preserving the essential cyclic tridecapeptide structure and C3 binding capability.
2Reliability
If amino acid modifications are introduced to improve solubility and pharmacokinetic properties, then therapeutic effectiveness is improved, but molecular complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (1, 3, 4, 6, 9, 13) of the compstatin peptide. These modifications include substituting residues with structurally similar alternatives (e.g., Valine with Isoleucine or Threonine) to maintain the cyclic structure and disulfide bridge while improving pharmacokinetic properties and solubility without compromising C3 binding activity.
Solution Approach 2:
The patent applies local quality by making targeted modifications at specific positions rather than uniform changes throughout the peptide. Each position (1, 3, 4, 6, 9, 13) has specific allowable substitutions based on structural and functional considerations, allowing optimization of particular properties (solubility, stability, activity) while preserving the essential cyclic tridecapeptide structure and C3 binding capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified compstatin analogues exhibit improved binding and complement-inhibiting activity, increased solubility, and potentially longer half-life, making them more effective therapeutic agents for autoimmune and inflammatory diseases.
Implementation Method 1
compstatin analogues that are capable of binding to C3 protein and inhibiting complement activation
Data Source
AI summary
Compstatin analogues having improved binding and complement-inhibiting activity as compared to the 13 amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)) (SEQ ID NO: 1) are described, in particular compstatin analogues that additionally possess useful physicochemical properties, such as increased solubility. These analogues include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing solubility, such as the introduction of charged or polar amino acids at position 9 and/or the introduction of N- and/or C-terminal sequences.